{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-036862","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2024-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.023562+00:00","generated_at":"2026-05-29T06:34:48.683443+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulse Biosciences CEO Barrett resigns; Danahy, Uecker named interim executives","bullets":["CEO Burke T. Barrett resigns effective Dec 6, 2024; also leaves board Dec 2, 2024.","Resignation not due to any disagreement; company affirms development and clinical plans on track.","Severance: 12 months base salary (24 installments), $106,009.61 bonus, partial vesting of 101,000 options at $7.45, COBRA.","Chief Commercial Officer Kevin Danahy and CTO Darrin Uecker serve as interim principal executive and financial officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-036862","json":"https://secwatch.observer/filing/0001437749-24-036862.json","markdown":"https://secwatch.observer/filing/0001437749-24-036862.md","text":"https://secwatch.observer/filing/0001437749-24-036862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924036862/0001437749-24-036862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924036862/plse20241206c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T06:34:48.683443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}